Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren in Nonsense-Mutation-Mediated Hemophilia A and B
NCT00947193Phase 2Terminated
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Oct 2009
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of ataluren in hemophilia A, hemophilia B (HB), sponsored by PTC Therapeutics, Inc.. Started Oct 2009; status: terminated.
02
Drugs
ataluren
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT00947193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00947193.